China

With ten other drugs in Phase III development by domestic companies, according to GlobalData’s Pharmaceutical Intelligence Center,…

GlobalData attributes this drop to price competition from local manufacturers and China’s ongoing anti-corruption crackdown on the…

The new services - CI6/SIS/CISC2 and SI8/AIS5 – offer expanded market access for Indian exporters and importers

Significant reforms in clinical development processes and regulatory reviews in China have led to faster drug approvals,…

Under the terms of the agreement, 3SBio will grant Pfizer an exclusive global license to develop, manufacture and commercialise…

Innovator drug deals involving Chinese biopharma reach $41.5 billion as licensing overtakes M&A for pipeline expansion, notes…

The company expands its global footprint with regulatory approval from China’s NMPA, reinforcing its leadership in antihistamine…

China represents the largest market for data and analytics in the pharmaceutical sector, contributing roughly 20.2 per cent of…

By FY 2023, Chinese imports accounted for 64 per cent of India’s IPA supply. Vikas Biyani – FDA Regulatory Consultant states that…

Leqembi is the only approved treatment in China that has shown efficacy in slowing the progression of Alzheimer’s by directly…